DM4-SPDB-acid serves as a drug-linker conjugate comprised of the maytansine-derived payload DM4, known for its tubulin-inhibiting properties, linked via an SPDB linker, resulting in a highly effective treatment with strong anti-tumor capabilities. It is suitable to be conjugated into antibody-drug conjugates (ADCs). The terminal carboxylic acid can react with primary amine groups in the presence of activators such as HATU. Please contact us for GMP-grade inquiries.
Usually ships within 24 hours.